


CLAIMS

1. A prevention and/or treatment agent for chronic obstructive pulmonary disease comprising a hydroxamic acid compound of formula (I)




wherein R¹ is (i) hydrogen, (ii) C1-8 alkyl or (iii) C1-8 alkyl substituted by -OR², in which R² is (i) hydrogen, (ii) C1-8 alkyl, (iii) benzyl, or (iv) C1-8 alkyl substituted by C1-8 alkoxy;

a salt thereof, a solvate thereof or a prodrug thereof as active ingredient.

2. The prevention and/or treatment agent for chronic obstructive pulmonary disease according to claim 1, wherein the compound is N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or N-hydroxy-5-ethoxymethyloxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide.


3. The prevention and/or treatment agent for chronic obstructive pulmonary disease according to claim 2, which is administered in an amount of 12.5 mg to 600 mg per day.

4. A pharmaceutical composition which comprises a hydroxamic acid compound of formula (I)



wherein all symbols are as claim 1; a salt thereof, a solvate thereof or a prodrug thereof, and one or at least two medicaments selected from anticholinergic agent, β_2 stimulator, theophylline products, leukotriene receptor antagonist, thromboxane synthetase inhibitor, thromboxane A_2 receptor antagonist, mediator release inhibitor, antihistamic agent, xanthine derivative, cytokine inhibitor, prostaglandins, forskolin, phosphodiesterase inhibitor, elastase inhibitor, aerosol steroid, expectorant, antibacterial agent.


5. Use of a hydroxamic acid compound of formula (I)



wherein all symbols are as claim 1, a salt thereof, a solvate thereof or a prodrug thereof for the manufacture of a medicament for prevention and/or treatment of chronic obstructive pulmonary disease.

6. The use according to claim 5, wherein the compound is N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or N-hydroxy-5-ethoxymethoxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide.

7. A method for prevention and/or treatment of chronic obstructive pulmonary disease in a mammal, which comprises administering to a mammal an effective amount of a hydroxamic acid compound of formula (I)



wherein all symbols are as claim 1; a salt thereof, a solvate thereof or a prodrug thereof.

8. The method for prevention and/or treatment according to claim 7, wherein the compound is N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or N-hydroxy-5-ethoxymethoxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide.